RxDoctor Payments DataLook up a doctor →

Sarah Sedlacek, APRN

Nurse Practitioner · Saint Joseph, MONPI 1295855351

Payments from drug & device makers

$11,836in general payments, 2019–2025

Across 400 payments — averaging $29.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$2K
  • Johnson & Johnson$962
  • Gilead$756
  • Takeda Pharmaceuticals U.S.A., Inc.$557
  • Phathom Pharmaceuticals, Inc.$550
  • plus $5K from 39 others

What the payments were for

  • Food & beverage$11,66799%
  • Education$1691%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,836 in reported general payments places this provider in the 95th percentile of 1,898 nurse practitioner providers in Missouri.

See all nurse practitioner providers in Missouri

Medicare billing

Part B allowed, 2024
$96,093
Medicare patients
623
Services billed
884

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZenpepLipase/Protease/Amylase11$154,231
LinzessLinaclotide73$64,858
CreonLipase/Protease/Amylase13$45,534
MotegrityPrucalopride Succinate38$22,698
Lubiprostone60$9,066
Pantoprazole Sodium364$4,734
Dexlansoprazole DrDexlansoprazole12$2,039
Esomeprazole Magnesium41$1,496
Famotidine95$1,400
Ondansetron OdtOndansetron46$1,251
Sucralfate53$1,204
Nortriptyline Hcl94$988
Omeprazole84$904
Dicyclomine Hcl35$654
Lansoprazole32$622

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aimmune Therapeutics, Inc.Zenpep$80$154,23111 claims
AbbVieLinzess, Creon$2,174$110,39286 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$557$22,69838 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,898 nurse practitioner providers in Missouri.

Other nurse practitioner in Saint Joseph

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →